CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Braveheart lands $383M IPO to take Hengrui cardio drug into Phase 3

IPO/OfferingPositive
AI Analysis

Summary

Braveheart Bio, a US biotech company derived from Hengrui Pharmaceuticals' pipeline, has priced a $383M IPO on Nasdaq to advance a cardiovascular drug candidate into Phase 3 trials.

Clinical Trial Data

Phase

3

Importance:7/10
Sentiment:
0.60
IPONasdaqChina-derived pipelinecardiologyPhase 3
Related Companies

Read the original article

Published by Endpoints News on August 6, 2026 6:56 AM

Read Original